RUNX1 and acute myeloid leukemia: A study revealed that ORI stimulated t(8;21) acute myeloid leukemia (AML) cell line apoptosis along with the degradation of AML1‐ETO (AE) fusion oncoprotein by targeting its D188 residue, with minimal side effects (Zhou et al., 2007).